Acrux Stock

Acrux EBIT

The EBIT of Acrux (ACR.AX) as of Jul 12, 2026 is -5.63 M AUD. In the previous year, EBIT was -5.57 M AUD — a change of 1.17% (lower).

EBIT

-5.63 MAUD

YoY

1.17%

Last updated:

In 2026, Acrux's EBIT was -5.63 M AUD, a 1.17% increase from the -5.57 M AUD EBIT recorded in the previous year.

The Acrux EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M AUD)
Date
EBIT (M AUD)
Jan 1, 2020
-9.49 base
Jan 1, 2021
-12.80 base
Jan 1, 2022
-9.58 base
Jan 1, 2023
0.11 base
Jan 1, 2024
-5.57 base
Jan 1, 2025
-5.63 base
Jan 1, 2026 (e)
10.37 base
Jan 1, 2027 (e)
5.18 base
YEAREBIT (M AUD)
2027 est 5.18
2026 est 10.37
2025 -5.63
2024 -5.57
2023 0.11
2022 -9.58
2021 -12.80
2020 -9.49
2019 -8.34
2018 -10.29
2017 11.04
2016 18.86
2015 16.64
2014 45.10
2013 9.91
2012 4.68
2011 84.42
2010 49.41
2009 -8.32
2008 -4.35
2007 -7.62
2006 -10.01
Access this data via the Eulerpool API

Acrux Revenue

Acrux Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
3.85 M AUD
-9.49 M AUD
-9.47 M AUD
Jan 1, 2021
4.79 M AUD
-12.80 M AUD
-12.63 M AUD
Jan 1, 2022
5.10 M AUD
-9.58 M AUD
-9.83 M AUD
Jan 1, 2023
11.93 M AUD
109,000.00 AUD
-764,000.00 AUD
Jan 1, 2024
8.10 M AUD
-5.57 M AUD
-5.80 M AUD
Jan 1, 2025
4.53 M AUD
-5.63 M AUD
-5.95 M AUD
Jan 1, 2026 (e)
20.34 M AUD
10.37 M AUD
12.77 M AUD
Jan 1, 2027 (e)
15.00 M AUD
5.18 M AUD
6.33 M AUD

Acrux Margins

Acrux stock margins

The Acrux margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Acrux. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Acrux.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
100.00 %
-246.68 %
-246.32 %
Jan 1, 2021
100.00 %
-267.03 %
-263.54 %
Jan 1, 2022
100.00 %
-187.77 %
-192.71 %
Jan 1, 2023
95.32 %
0.91 %
-6.41 %
Jan 1, 2024
51.14 %
-68.76 %
-71.62 %
Jan 1, 2025
100.00 %
-124.40 %
-131.29 %
Jan 1, 2026 (e)
100.00 %
50.99 %
62.78 %
Jan 1, 2027 (e)
100.00 %
34.51 %
42.20 %

Acrux Stock analysis

What does Acrux do? Acrux Ltd is an Australian pharmaceutical company specializing in the development and marketing of products in the dermatology field. The company was founded in 1998 and is headquartered in Melbourne. Its history begins with the development of a groundbreaking technology called the "Sprayform® Technology," which allows the administration of liquid medications in spray form, providing numerous advantages compared to traditional administration methods. Acrux obtained the first patent for this technology in 1999 and worked on bringing it to the market. Its business model focuses on licensing its Sprayform® Technology to third parties to advance the development and marketing of products in various therapeutic areas. The company has an experienced research and development team that collaborates closely with partners to develop tailored solutions and support the entire development process, ensuring that all products meet the highest quality standards and regulatory requirements. Acrux Ltd is divided into various divisions, including products for women, diabetes, pain and inflammation, as well as neurology and psychiatry. With its Sprayform® Technology, the company has developed unique therapeutic solutions that meet patients' needs. For example, a testosterone preparation for women has been developed that is simply applied as a spray and offers higher efficacy than traditional tablets. Another product is a fast-acting pain reliever that is administered through a nasal spray. Acrux Ltd also has partnerships with major pharmaceutical companies such as Eli Lilly, Johnson & Johnson, Pfizer, and Sanofi. These partnerships enable Acrux to market its technology globally and offer its customers a comprehensive portfolio of tailored solutions. The partner is granted exclusive rights to use the technology for specific products and markets, facilitating the development of new products and the expansion into new regions. Overall, Acrux Ltd has achieved a leadership position in the field of transdermal systems and transmucosal technologies through its innovative Sprayform® Technology. The company aims to further expand its leadership position by focusing on the development of new products and collaboration with partners. Acrux remains in constant exchange with the scientific community to incorporate the latest research and development insights into its products. Acrux is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Acrux's EBIT

Acrux's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Acrux's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Acrux's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Acrux’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Acrux stock

EBIT of Acrux is -5.63 M AUD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Acrux

All Key Metrics — Acrux